Screener
BridgeBio Pharma BBIO Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $29,058 | $36,228 |
| Accrued compensation and benefits | 39,338 | 76,703 |
| Accrued research and development liabilities | 54,430 | 41,436 |
| Operating lease liabilities, current portion | 4,439 | 6,192 |
| Deferred revenue, current portion | 6,115 | 7,190 |
| 2027 Notes, net | 547,483 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's accrued manufacturing costs?
- BridgeBio Pharma (BBIO) reported accrued manufacturing costs of $39.34M in Q1 2026.
- How has BridgeBio Pharma's accrued manufacturing costs changed year-over-year?
- BridgeBio Pharma's accrued manufacturing costs increased by 17.6% year-over-year, from $33.45M to $39.34M.
- What is the long-term trend for BridgeBio Pharma's accrued manufacturing costs?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accrued manufacturing costs has grown at a 20.9% compound annual growth rate (CAGR), from $29.68M to $76.7M.
Ask your AI about BridgeBio Pharma's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude